New hope for Hard-to-Treat nasopharyngeal cancer: ivonescimab trial launches
NCT ID NCT07565389
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing a drug called ivonescimab in 42 people with a type of head and neck cancer (nasopharyngeal carcinoma) that has stopped responding to standard immunotherapy and chemotherapy. The drug is given every 3 weeks by IV. Researchers will measure how many patients' tumors shrink and how long they live without the cancer growing. The goal is to see if ivonescimab can offer a new treatment option for this difficult-to-treat cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ivonescimab
- What this could lead to
- If successful, this could offer a new treatment option for patients with nasopharyngeal carcinoma that has stopped responding to standard immunotherapy.
- What could go wrong
- This is a small, early-phase trial with only 42 participants and no comparison group. The drug may not work better than existing options and could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CARCINOMA (NPC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National University Cancer Institute, Singapore, National University Health System
Singapore, Singapore
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could avoiding Pre-Radiation tooth removal protect jaw health?
- Can a blood test and MRI tailor cancer therapy to each patient?
- Can an immunotherapy boost standard treatment for a Head-and-Neck cancer?
- Can a Two-Pronged radiation strategy boost immunotherapy against advanced nasopharyngeal cancer?
- Can tumor genetics predict survival in nasopharyngeal cancer?
- Dual-Action antibody may boost chemoradiotherapy against High-Risk nasopharyngeal cancer